Lale Tokgözoğlu, MD, FACC, FESC is Professor of Cardiology at Hacettepe University, Ankara, Turkey. She is currently the immediate Past-President of the European Atherosclerosis Society and Deputy Editor of the European Heart Journal. She chaired the ‘Atherosclerosis and Vascular Biology Working Group of the European Society of Cardiology’ between 2008 and 2010.

Prof. Tokgözoğlu has served on the Board of the Turkish Society of Cardiology and was elected to be the first female President of the Society in its history, between 2014-2016. During that time, she worked with the Ministry of Health to develop ‘Heart Health policies’ and strategies. She also chaired the Dyslipidaemia Working Group of the Turkish Society of Cardiology.

She has contributed to several Guidelines and Consensus Papers on dyslipidaemia and Preventive Cardiology both in Europe and nationally. She was a member of the Steering Committee of the EUROASPIRE III-V studies which were the landmark studies defining preventive measures in Europe. She has also served on the Board of the Prevention Association as well as different committees of the European Society of Cardiology including the Fellowship and Training Committee, the Education Committee and currently the Research and Grants Committee. She is a member of the Science Academy and a founding member of the Atherosclerosis Research and Education Society in Turkey. She is founding member of the Department of Noncommunicable diseases in Hacettepe University. She serves on the Scientific and Research Council of Turkey Working Group on women researchers.

Awards:

Metrodora Award Global Leader in Science and Health 2020

Istanbul Medical Association Science Award in 2019

Paul Dudley White Science team award AHA 2017

Prof. Dr. Şeref Zileli Resident of the Year” Award in 1987

Young Investigator Award of the Turkish Society of Cardiology in 1994

Contributions

Women and cardiovascular diseasePanel Discussion: How can we reduce cardiovascular risk targeting inflammation via IL-6_91th EAS Congress 2023How can we reduce cardiovascular risk targeting inflammation via IL-6_Targeting inflammation in atherosclerotic cardiovascular disease: What are our options and where do we stand?91th EAS Congress 2023How can we reduce cardiovascular risk targeting inflammation via IL-6_Panel Discussion: ESC/EAS joint session - Image-guided therapy and prevention for ASCVD91th EAS Congress 2023ESC/EAS joint session - Image-guided therapy and prevention for ASCVDPanel Discussion: Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?91th EAS Congress 2023Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?Panel Discussion: Re-thinking Lipid Management in Patients with High and Very High Cardiovascular Risk91th EAS Congress 2023Re-thinking Lipid Management in Patients with High and Very High Cardiovascular RiskA deep dive into CLEAR OUTCOMES and its implicationsWebinars on-demandLCN Lp(a) webinar series #5: Round table with the experts – How to use L(a) in practice, from the point of view of the cardiologist, the lipidologist, the diabetologist and the patientWebinars on-demandLCN Lp(a) webinar series #1: Lp(a) - what it is, and its role in atherosclerosisWebinars on-demandEAS Advanced Course, Rare Lipid Disorders in Turkey. Nadir Lipid Bozuklukları -TürkiyeWebinars on-demandNLA/EAS joint session - Primordial prevention: The neglected topic - Discussion and Q&ANLA/EAS joint session - Primordial prevention: The neglected topic90th EAS Congress 2022Why do we need primordial prevention?NLA/EAS joint session - Primordial prevention: The neglected topic90th EAS Congress 2022Why and how to implement early combination lipid lowering therapy - Discussion and Q&A90th EAS Congress 2022Why and how to implement early combination lipid lowering therapyHow can we optimise lipid lowering after acute coronary syndromes?90th EAS Congress 2022Why and how to implement early combination lipid lowering therapyReimagining population health-the time is now - Discussion and Q&AReimagining population health-the time is now90th EAS Congress 2022Reimagining imaging to guide intensity of treatment - who what and how?Reimagining population health-the time is now90th EAS Congress 2022Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention - Discussion and Q&A90th EAS Congress 2022Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD PreventionWomen, dyslipidaemia and atherosclerosisWebinars on-demandLipids and atherosclerosis in COVID eraWebinars on-demandFrom risk factors to acute coronary syndrome in women89th EAS Congress 2021CV disease risk classificationIntro to Clinical LipidologyCourse presentations - An Introduction to Clinical Lipidology, October 2019Intro to Clinical LipidologyNew and old lipid-lowering drugsEAS AC on Epidemiology & GeneticsCVD - Epidemiology of the risk factors - the central role of LDL cholesterolEAS AC in LipidologyStatins, including intoleranceAn Introduction to Clinical LipidologyManagement of dyslipidaemic patients in clinical practiceAn Introduction to Clinical LipidologyGuidelines - ACS & very high risk patientsAn Introduction to Clinical LipidologyEAS IntroductionAn Introduction to Clinical LipidologyCV disease risk classificationAn Introduction to Clinical LipidologyWhat is the landscape on lipid management today?88th EAS Congress 2020Physician-Patient relationship - Challenges and opportunities87th EAS Congress 2019Science versus reality in long term management - Time for a paradigm shift?86th EAS Congress 2018Introduction to Detecting plaque burden or vulnerable plaque - Which way should we go?85th EAS Congress 2017Introduction to Anitschkow prize winner85th EAS Congress 2017Combination therapy a better way to treat?85th EAS Congress 2017An Introduction to Clinical Lipidology2019 Intro to Clinical LipidologyThe approach of high - and very high risk patients in the new guidelines2019 ESC-EAS Dyslipidaemia GuidelinesDyslipidaemia treatment in ACS2019 ESC-EAS Dyslipidaemia Guidelines